Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisonke Boost
NCT05148845Phase 3Completed
- Sponsor
- Wits Health Consortium
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19), sponsored by Wits Health Consortium. Primary endpoint: Effectiveness of Ad26.COV2.S boost vaccine on severe COVID, hospitalizations and deaths compared to unboosted at 24 months. Started Nov 2021; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05148845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148845.